Clinical Trial

JS207 Combination Therapy in Triple-negative Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, multi-center, phase II clinical study to preliminarily evaluate the efficacy and safety of JS207 combined with 9MW2821 or albumin paclitaxel as first-line therapy in patients with recurrent or metastatic TNBC.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-06-23; most recent amendment 2026-04-10.
Status change: Not Yet Recruiting → Recruiting 2025-09-23
Trial Details
NCT Number NCT07045311
Lead Sponsor Shanghai Junshi Bioscience Co., Ltd.
Conditions Triple-negative Breast Cancer
Enrollment 80 participants
Start Date 2025-09-17
Primary Completion 2028-03-22 (estimated)
Study Completion 2029-03-22 (estimated)
Updated on ClinicalTrials.gov 2026-04-15